HRP20190434T1 - Fuzijski protein - Google Patents
Fuzijski proteinInfo
- Publication number
- HRP20190434T1 HRP20190434T1 HRP20190434TT HRP20190434T HRP20190434T1 HR P20190434 T1 HRP20190434 T1 HR P20190434T1 HR P20190434T T HRP20190434T T HR P20190434TT HR P20190434 T HRP20190434 T HR P20190434T HR P20190434 T1 HRP20190434 T1 HR P20190434T1
- Authority
- HR
- Croatia
- Prior art keywords
- fusion protein
- fusion
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2807—Headache; Migraine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1316592.3A GB201316592D0 (en) | 2013-09-18 | 2013-09-18 | Fusion protein |
| EP14772194.8A EP3046934B1 (en) | 2013-09-18 | 2014-09-18 | Fusion protein |
| PCT/GB2014/052833 WO2015040398A1 (en) | 2013-09-18 | 2014-09-18 | Fusion protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190434T1 true HRP20190434T1 (hr) | 2019-04-19 |
Family
ID=49552839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190434TT HRP20190434T1 (hr) | 2013-09-18 | 2014-09-18 | Fuzijski protein |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US9873728B2 (hr) |
| EP (1) | EP3046934B1 (hr) |
| JP (3) | JP6681834B2 (hr) |
| KR (1) | KR102205633B1 (hr) |
| CN (1) | CN105873943B (hr) |
| AU (1) | AU2014322842B2 (hr) |
| CA (1) | CA2924410C (hr) |
| CY (1) | CY1121347T1 (hr) |
| DK (1) | DK3046934T3 (hr) |
| EA (1) | EA037416B1 (hr) |
| ES (1) | ES2714694T3 (hr) |
| GB (1) | GB201316592D0 (hr) |
| HR (1) | HRP20190434T1 (hr) |
| HU (1) | HUE043273T2 (hr) |
| IL (1) | IL244588B (hr) |
| LT (1) | LT3046934T (hr) |
| MX (1) | MX375514B (hr) |
| NZ (1) | NZ718044A (hr) |
| PL (1) | PL3046934T3 (hr) |
| PT (1) | PT3046934T (hr) |
| RS (1) | RS58463B1 (hr) |
| SG (1) | SG11201602068QA (hr) |
| SI (1) | SI3046934T1 (hr) |
| SM (1) | SMT201900122T1 (hr) |
| TR (1) | TR201903490T4 (hr) |
| WO (1) | WO2015040398A1 (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201491550A1 (ru) | 2012-03-14 | 2014-12-30 | Левисепт Лтд. | Применение связывающего белка нейротрофинового рецептора p75ntr в терапевтических целях |
| GB201316592D0 (en) | 2013-09-18 | 2013-10-30 | Levicept Ltd | Fusion protein |
| GB201412748D0 (en) * | 2014-07-17 | 2014-09-03 | Levicept Ltd | Therapeutic use of P75NTR neurotrophin binding protein |
| GB201504691D0 (en) | 2015-03-19 | 2015-05-06 | Levicept Ltd | Fusion protein |
| EP3711772A1 (en) | 2019-03-20 | 2020-09-23 | Oslo Universitetssykehus HF | Recombinant proteins and fusion proteins |
| CN113456799A (zh) * | 2020-12-25 | 2021-10-01 | 苏州澳宗生物科技有限公司 | 一种p75ECD在制备用于调节疼痛的药物中的应用 |
| CN112851794B (zh) * | 2021-02-04 | 2023-05-23 | 苏州铂维生物科技有限公司 | 一种基于cd271的抗原表位及其应用 |
| JP2024542958A (ja) * | 2021-10-21 | 2024-11-19 | ペットメディックス・リミテッド | Ｐ７５ｎｔｒの細胞外ドメインを含むタンパク質 |
| US11608371B1 (en) | 2021-10-21 | 2023-03-21 | Petmedix Ltd | Therapeutic molecules |
| WO2024165857A1 (en) * | 2023-02-08 | 2024-08-15 | Levicept Limited | Fusion protein |
| WO2024165872A1 (en) * | 2023-02-09 | 2024-08-15 | Petmedix Ltd | Therapeutic molecules comprising variants of the extracellular domain of p75 neurotrophin receptor (p75ntr) |
| GB202307936D0 (en) * | 2023-05-26 | 2023-07-12 | Levicept Ltd | Fusion protein |
| GB202400055D0 (en) | 2024-01-03 | 2024-02-14 | Tribune Therapeutics Ab | Use of ccn domain-containing proteins for the treatment of disease |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9022648D0 (en) | 1990-10-18 | 1990-11-28 | Charing Cross Sunley Research | Polypeptide and its use |
| FR2686900B1 (fr) * | 1992-01-31 | 1995-07-21 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant. |
| US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| WO2005037867A1 (en) | 2003-10-15 | 2005-04-28 | Pdl Biopharma, Inc. | ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG |
| JP2008528006A (ja) * | 2005-01-28 | 2008-07-31 | アポロ ライフ サイエンシズ リミテッド | 分子およびそのキメラ分子 |
| JPWO2007026567A1 (ja) | 2005-08-30 | 2009-03-05 | 国立大学法人 千葉大学 | ｐ７５ＮＴＲ阻害剤を有効成分として含有する鎮痛剤 |
| AU2006326870A1 (en) * | 2005-12-22 | 2007-06-28 | Apollo Life Sciences | Transdermal delivery of pharmaceutical agents |
| GB0717985D0 (en) * | 2007-07-20 | 2007-10-24 | Asterion Ltd | Growth hormone fusion proteins |
| US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| US20100061981A1 (en) | 2008-08-15 | 2010-03-11 | The Salk Institute For Biological Studies | p75NTR MEDIATES EPHRIN-A REVERSE SIGNALING |
| US9051359B2 (en) * | 2009-03-30 | 2015-06-09 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccines and uses thereof |
| WO2011047267A1 (en) * | 2009-10-15 | 2011-04-21 | Genentech, Inc. | Chimeric fibroblast growth factors with altered receptor specificity |
| RU2012127383A (ru) | 2009-12-02 | 2014-01-10 | Акселерон Фарма Инк. | Композиции и способы для увеличения времени полужизни fc-слитых белков в сыворотке |
| CN102233128B (zh) | 2010-11-26 | 2013-04-17 | 王延江 | 一种p75NTR-ECD在防治阿尔茨海默病药物中应用 |
| ITRM20110024A1 (it) * | 2011-01-24 | 2012-07-25 | Consiglio Nazionale Ricerche | Uso di antagonisti del recettore p75ntr e/o di agonisti del recettore trka per il trattamento delle malattie infiammatorie croniche. |
| WO2013026837A1 (en) * | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| TWI476001B (zh) * | 2011-12-26 | 2015-03-11 | Ind Tech Res Inst | 三倍體Ｆｃ融合蛋白及其用途 |
| CN102586313A (zh) | 2012-03-05 | 2012-07-18 | 中国人民解放军第三军医大学野战外科研究所 | p75NTR-ED-Fc融合蛋白的制备方法及其在损伤中枢神经再生与功能恢复中的应用 |
| EA201491550A1 (ru) | 2012-03-14 | 2014-12-30 | Левисепт Лтд. | Применение связывающего белка нейротрофинового рецептора p75ntr в терапевтических целях |
| EP2674439B1 (en) * | 2012-06-13 | 2017-02-01 | Rottapharm Biotech S.r.l. | Anti-TrkA antibodies, derivatives and uses thereof |
| GB201316592D0 (en) | 2013-09-18 | 2013-10-30 | Levicept Ltd | Fusion protein |
| GB201412748D0 (en) * | 2014-07-17 | 2014-09-03 | Levicept Ltd | Therapeutic use of P75NTR neurotrophin binding protein |
| GB201504691D0 (en) * | 2015-03-19 | 2015-05-06 | Levicept Ltd | Fusion protein |
-
2013
- 2013-09-18 GB GBGB1316592.3A patent/GB201316592D0/en not_active Ceased
-
2014
- 2014-09-18 EA EA201690469A patent/EA037416B1/ru unknown
- 2014-09-18 HU HUE14772194A patent/HUE043273T2/hu unknown
- 2014-09-18 SG SG11201602068QA patent/SG11201602068QA/en unknown
- 2014-09-18 AU AU2014322842A patent/AU2014322842B2/en active Active
- 2014-09-18 PT PT14772194T patent/PT3046934T/pt unknown
- 2014-09-18 SM SM20190122T patent/SMT201900122T1/it unknown
- 2014-09-18 ES ES14772194T patent/ES2714694T3/es active Active
- 2014-09-18 RS RS20190259A patent/RS58463B1/sr unknown
- 2014-09-18 PL PL14772194T patent/PL3046934T3/pl unknown
- 2014-09-18 LT LTEP14772194.8T patent/LT3046934T/lt unknown
- 2014-09-18 JP JP2016543457A patent/JP6681834B2/ja active Active
- 2014-09-18 EP EP14772194.8A patent/EP3046934B1/en active Active
- 2014-09-18 CA CA2924410A patent/CA2924410C/en active Active
- 2014-09-18 WO PCT/GB2014/052833 patent/WO2015040398A1/en active Application Filing
- 2014-09-18 MX MX2016003530A patent/MX375514B/es active IP Right Grant
- 2014-09-18 KR KR1020167010006A patent/KR102205633B1/ko active Active
- 2014-09-18 CN CN201480060027.8A patent/CN105873943B/zh active Active
- 2014-09-18 DK DK14772194.8T patent/DK3046934T3/en active
- 2014-09-18 US US15/022,505 patent/US9873728B2/en active Active
- 2014-09-18 SI SI201431067T patent/SI3046934T1/sl unknown
- 2014-09-18 TR TR2019/03490T patent/TR201903490T4/tr unknown
- 2014-09-18 NZ NZ718044A patent/NZ718044A/en unknown
- 2014-09-18 HR HRP20190434TT patent/HRP20190434T1/hr unknown
-
2016
- 2016-03-14 IL IL244588A patent/IL244588B/en active IP Right Grant
-
2017
- 2017-12-15 US US15/844,022 patent/US10988526B2/en active Active
-
2019
- 2019-03-08 CY CY20191100281T patent/CY1121347T1/el unknown
- 2019-10-29 JP JP2019195922A patent/JP2020062011A/ja active Pending
-
2021
- 2021-03-24 US US17/211,362 patent/US20210238256A1/en active Pending
-
2022
- 2022-02-10 JP JP2022019327A patent/JP7357088B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL284301A (en) | Heterodimeric proteins | |
| DK3292141T3 (da) | Fusionsproteiner | |
| DK3180363T3 (da) | Sirp-alpha-immunoglobulin fusionsproteiner | |
| DK3336106T3 (da) | Anti-fcrh5-antistoffer | |
| DK2970464T3 (da) | Anti-lag-3-bindende proteiner | |
| DK3342773T3 (da) | Syk-hæmmere | |
| DK3708583T3 (da) | Ikke-fucosylerede anti-fgfr2iiib-antistoffer | |
| DK2970441T3 (da) | AGLYCOSYLEREDE Fc-INDEHOLDENDE POLYPEPTIDER | |
| DK3004155T3 (da) | Peptidforbindelse | |
| DK3041857T3 (da) | Protein a-kromatografi | |
| CL2016000219A1 (es) | Proteinas de fusión terapéutica. | |
| HUE043273T2 (hu) | Fúziós fehérje | |
| DK3107562T3 (da) | P97-ids-fusionsproteiner | |
| EP2986098A4 (en) | Splicing device | |
| BR112016000140A2 (pt) | Articulação ortésica | |
| DK3068800T3 (da) | FcRn-specifikke antistoffer | |
| EP2982408A4 (en) | INTERCONNECTS | |
| EP3556542C0 (en) | IMPROVED ELECTROFUSION JOINING PROCESSES | |
| IL240474A0 (en) | Cross-linking proteins that bind to cartilage | |
| HRP20180452T1 (hr) | Peptidi | |
| EP2969009A4 (en) | MODIFIED FC FUSION PROTEINS | |
| EP2969728C0 (en) | HANDLE-POWERED VELOCIPEDE | |
| DK3065774T3 (da) | Anti-CCL17-antistoffer | |
| UA27558S (uk) | Лінза | |
| DK3089990T3 (da) | Forbedret proteinekspression |